Pharmaceutical Industry Sees Surge in Sales and Technological Advancements

Beta Bionics, a newly public insulin pump manufacturer, reported a significant sales increase in its first quarterly results since going public. Meanwhile, Dexcom appointed a new chief commercial officer, and Sibionics received CE mark approval for its latest continuous glucose monitoring (CGM) device.

Beta Bionics Reports Strong Q4 Performance

Beta Bionics, which went public in January 2025 raising $204 million in an upsized initial public offering, announced a 145% increase in sales for the fourth quarter, reaching $20.4 million. This figure exceeded Wall Street analysts' expectations by 2%, according to Leerink Partners.

The company's growth was driven by nearly 4,100 new patient starts, positioning it at the high end of its forecasted range. Leerink analysts highlighted "better-than-expected pharmacy adoption" as a positive factor, with Beta Bionics signing two large formulary contracts in late 2024 and early 2025.

The pharmacy channel is expected to account for more than 20% of new patient starts this year, potentially providing "clear tailwinds to both the top and bottom line in the intermediate to long term," according to Leerink analysts.

Dexcom Appoints New Chief Commercial Officer Amid Restructuring

Dexcom, a leading glucose biosensing company, has named Jon Coleman as its new chief commercial officer. Coleman, who spent 15 years at patient monitoring company Masimo, will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

This appointment comes after Dexcom lowered its revenue forecast last year amid a restructuring of its salesforce. However, CEO Kevin Sayer reported in a recent earnings call that newly hired workers have "now become more productive."

Coleman's appointment follows the retirement of Teri Lawver, Dexcom's first chief commercial officer, who left the company at the end of last year. Sayer had been leading the commercial team in the interim.

Sibionics Receives CE Mark for Ultra-Thin CGM

Chinese medtech company Sibionics has obtained CE mark approval for its GS3 continuous glucose monitor. The company claims the 2.9mm thick device is the world's thinnest CGM, weighing just 1.5g.

The GS3 features near field communication capabilities, allowing users to pair other devices by tapping them on the CGM. It also incorporates artificial intelligence to help users "better understand their glucose data" and "enable more effective self-management" of glucose levels.

Sibionics' GS3 competes with established players in the CGM market. For comparison, Dexcom's G7 is 4.7mm thick and weighs 3.3g, while Abbott's Freestyle Libre 3 matches the GS3's thickness at 2.9mm but weighs slightly less at 1g.

The CE mark approval for GS3 follows Sibionics' earlier success with its GS1 model, which received CE mark approval in 2023. The company, which employs 500 people across offices in China and California, also claims to be the first to receive approval for a fingerstick-free CGM in China in 2021.